BIT:1BMY - Euronext Milan - US1101221083 - Common Stock - Currency: EUR
BIT:1BMY (5/27/2025, 7:00:00 PM)
41.495
+0.26 (+0.63%)
The current stock price of 1BMY.MI is 41.495 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 57.77 | 644.46B | ||
LLY.DE | ELI LILLY & CO | 56.5 | 630.25B | ||
ZEG.DE | ASTRAZENECA PLC | 16.66 | 381.66B | ||
JNJ.DE | JOHNSON & JOHNSON | 15.54 | 321.60B | ||
1JNJ.MI | JOHNSON & JOHNSON | 15.49 | 320.58B | ||
NOV.DE | NOVO NORDISK A/S-B | 18.48 | 258.60B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.58 | 238.41B | ||
NOT.DE | NOVARTIS AG-REG | 14.6 | 204.50B | ||
SNW.DE | SANOFI | 10.87 | 203.47B | ||
1SAN.MI | SANOFI | 10.84 | 202.94B | ||
SAN.PA | SANOFI | 10.75 | 201.38B | ||
6MK.DE | MERCK & CO. INC. | 10.78 | 180.29B |
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 16092524621
The current stock price of 1BMY.MI is 41.495 EUR. The price increased by 0.63% in the last trading session.
The exchange symbol of BRISTOL-MYERS SQUIBB CO is 1BMY and it is listed on the Euronext Milan exchange.
1BMY.MI stock is listed on the Euronext Milan exchange.
32 analysts have analysed 1BMY.MI and the average price target is 49.08 EUR. This implies a price increase of 18.28% is expected in the next year compared to the current price of 41.495. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a market capitalization of 84.45B EUR. This makes 1BMY.MI a Large Cap stock.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) currently has 34100 employees.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a support level at 41.23. Check the full technical report for a detailed analysis of 1BMY.MI support and resistance levels.
The Revenue of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is expected to decline by -3.36% in the next year. Check the estimates tab for more information on the 1BMY.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a dividend yield of 4.89%. The yearly dividend amount is currently 2.1. Check the full fundamental report for a detailed analysis of 1BMY.MI dividend history, reliability and sustainability.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) will report earnings on 2025-07-31, before the market open.
The PE ratio for BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 6.5. This is based on the reported non-GAAP earnings per share of 6.38 and the current share price of 41.495 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1BMY.MI.
ChartMill assigns a technical rating of 3 / 10 to 1BMY.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1BMY.MI. 1BMY.MI has only an average score on both its financial health and profitability.
Over the last trailing twelve months 1BMY.MI reported a non-GAAP Earnings per Share(EPS) of 6.38. The EPS increased by 599.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 11.38% | ||
ROA | 5.86% | ||
ROE | 31.16% | ||
Debt/Equity | 2.67 |
ChartMill assigns a Buy % Consensus number of 68% to 1BMY.MI. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 509.67% and a revenue growth -3.36% for 1BMY.MI